206 related articles for article (PubMed ID: 29649923)
21. CMV meningitis associated with dimethyl fumarate therapy-induced lymphopenia in a multiple sclerosis patient.
Kogel AK; Gold R; Schneider R
J Neurol; 2021 Nov; 268(11):4374-4375. PubMed ID: 34175973
[No Abstract] [Full Text] [Related]
22. Predictors of hematological abnormalities in multiple sclerosis patients treated with fingolimod and dimethyl fumarate and impact of treatment switch on lymphocyte and leukocyte count.
Baharnoori M; Gonzalez CT; Chua A; Diaz-Cruz C; Healy BC; Stankiewicz J; Weiner HL; Chitnis T
Mult Scler Relat Disord; 2018 Feb; 20():51-57. PubMed ID: 29304497
[TBL] [Abstract][Full Text] [Related]
23. Safety and persistence of dimethyl fumarate as a treatment for relapsing-remitting multiple-sclerosis.
Boullosa-Lale S; González-Freire L; Martínez-Martínez L; Crespo-Diz C
Farm Hosp; 2020 Dec; 45(2):73-76. PubMed ID: 33709887
[TBL] [Abstract][Full Text] [Related]
24. Tolerability and safety of dimethyl fumarate in relapsing multiple sclerosis: a prospective observational multicenter study in a real-life Spanish population.
Sabin J; Urtiaga S; Pilo B; Thuissard I; Galan V; Sainz de la Maza S; Costa-Frossard L; Gómez-Moreno M; Díaz-Díaz J; Oreja-Guevara C; Martínez-Ginés ML; Lozano A; Borrega L; Ayuso L; Castro A; Sanchez P; Meca-Lallana V; Muñoz C; Casanova I; López de Silanes C; Martín H; Rodriguez-García E; Moreno I; García-Merino JA; Aladro Y;
J Neurol; 2020 Aug; 267(8):2362-2371. PubMed ID: 32350647
[TBL] [Abstract][Full Text] [Related]
25. An evaluation of dimethyl fumarate for the treatment of relapsing remitting multiple sclerosis.
Valencia-Sanchez C; Carter JL
Expert Opin Pharmacother; 2020 Aug; 21(12):1399-1405. PubMed ID: 32543241
[TBL] [Abstract][Full Text] [Related]
26. Dimethyl fumarate induces changes in B- and T-lymphocyte function independent of the effects on absolute lymphocyte count.
Longbrake EE; Cantoni C; Chahin S; Cignarella F; Cross AH; Piccio L
Mult Scler; 2018 May; 24(6):728-738. PubMed ID: 28480794
[TBL] [Abstract][Full Text] [Related]
27. Severe multiple sclerosis reactivation during prolonged lymphopenia after dimethyl fumarate discontinuation.
Zecca C; Antozzi CG; Torri Clerici V; Ferrazzini M; Mantegazza RE; Rossi S; Gobbi C
Acta Neurol Scand; 2018 Jun; 137(6):623-625. PubMed ID: 29205270
[TBL] [Abstract][Full Text] [Related]
28. Incidence of persistent lymphopenia in people with multiple sclerosis on dimethyl fumarate.
Wood CH; Robertson NP; Htet ZM; Tallantyre EC
Mult Scler Relat Disord; 2022 Feb; 58():103492. PubMed ID: 35066268
[TBL] [Abstract][Full Text] [Related]
29. Factors associated with dimethyl fumarate-induced lymphopenia.
Sainz de la Maza S; Medina S; Villarrubia N; Costa-Frossard L; Monreal E; Tejeda-Velarde A; Rodríguez-Martín E; Roldán E; Álvarez-Cermeño JC; Villar LM
J Neurol Sci; 2019 Mar; 398():4-8. PubMed ID: 30658226
[TBL] [Abstract][Full Text] [Related]
30. Safety and Efficacy of Dimethyl Fumarate in Multiple Sclerosis: An Italian, Multicenter, Real-World Study.
Mirabella M; Prosperini L; Lucchini M; Boffa L; Borriello G; Buscarinu MC; Centonze D; Cortese A; De Fino C; De Giglio L; Elia G; Fantozzi R; Ferraro E; Francia A; Galgani S; Gasperini C; Haggiag S; Landi D; Marfia GA; Millefiorini E; Monteleone F; Nociti V; Salvetti M; Sgarlata E; Pozzilli C
CNS Drugs; 2018 Oct; 32(10):963-970. PubMed ID: 30022464
[TBL] [Abstract][Full Text] [Related]
31. Real-life persistence and tolerability with dimethyl fumarate.
Sejbaek T; Nybo M; Petersen T; Illes Z
Mult Scler Relat Disord; 2018 Aug; 24():42-46. PubMed ID: 29906666
[TBL] [Abstract][Full Text] [Related]
32. Improving the Gastrointestinal Tolerability of Fumaric Acid Esters: Early Findings on Gastrointestinal Events with Diroximel Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis from the Phase 3, Open-Label EVOLVE-MS-1 Study.
Palte MJ; Wehr A; Tawa M; Perkin K; Leigh-Pemberton R; Hanna J; Miller C; Penner N
Adv Ther; 2019 Nov; 36(11):3154-3165. PubMed ID: 31538304
[TBL] [Abstract][Full Text] [Related]
33. Dimethyl fumarate induced lymphopenia in multiple sclerosis: A review of the literature.
Dello Russo C; Scott KA; Pirmohamed M
Pharmacol Ther; 2021 Mar; 219():107710. PubMed ID: 33091427
[TBL] [Abstract][Full Text] [Related]
34. Transient hair loss during treatment with dimethyl-fumarate for multiple sclerosis.
Losavio FA; Lucchini M; De Fino C; Mirabella M; Nociti V
Mult Scler Relat Disord; 2016 May; 7():68-9. PubMed ID: 27237761
[TBL] [Abstract][Full Text] [Related]
35. Legionella infection associated with dimethyl fumarate used for treatment of multiple sclerosis.
Rastas C; Sirignano D; Barner A; Bruno-Murtha LA
J Neurol; 2019 Nov; 266(11):2867-2868. PubMed ID: 31350640
[No Abstract] [Full Text] [Related]
36. Delayed and recurrent dimethyl fumarate induced-lymphopenia in patients with multiple sclerosis.
Borrelli S; Mathias A; Goff GL; Pasquier RD; Théaudin M; Pot C
Mult Scler Relat Disord; 2022 Jul; 63():103887. PubMed ID: 35636269
[TBL] [Abstract][Full Text] [Related]
37. Increased multiple sclerosis disease activity in patients transitioned from fingolimod to dimethyl fumarate: a case series.
Delgado S; Hernandez J; Tornes L; Rammohan K
BMC Neurol; 2021 Feb; 21(1):48. PubMed ID: 33530945
[TBL] [Abstract][Full Text] [Related]
38. Progressive multifocal leukoencephalopathy in dimethyl fumarate-treated multiple sclerosis patients.
Jordan AL; Yang J; Fisher CJ; Racke MK; Mao-Draayer Y
Mult Scler; 2022 Jan; 28(1):7-15. PubMed ID: 32808554
[TBL] [Abstract][Full Text] [Related]
39. Acute pancreatitis: possible association of dimethyl fumarate for the treatment of relapsing-remitting multiple sclerosis.
Luo H; Bhatt H; Mohamad S; Uhrik E; Sen S; Mathew T; Yousif A
J Neurol; 2015 Mar; 262(3):779-80. PubMed ID: 25626723
[No Abstract] [Full Text] [Related]
40. Effects of dimethyl fumarate on lymphocyte subsets.
Berkovich R; Weiner LP
Mult Scler Relat Disord; 2015 Jul; 4(4):339-41. PubMed ID: 26195053
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
